Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-501 in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
NCT03594227Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATI-501 in alopecia areata, alopecia universalis (AU), alopecia totalis (AT), sponsored by Aclaris Therapeutics, Inc.. Started Jun 2018; status: completed.
02
Drugs
ATI-501
03
Conditions
alopecia areataalopecia universalis (AU)alopecia totalis (AT)
Beyond the preview
Go deeper on NCT03594227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594227.